Growth hormone therapy with three dosage regimens in children with idiopathic short stature
| Autor: | E. Leiberman, Lyset Rekers-Mombarg, Jan M. Wit, Jean-Louis Chaussain, Guy Massa, O. Butenandt, Herwig Frisch, R. Yturriaga, Anna M.C. Matranga, J. M. H. Buckler |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Pediatrics
medicine.medical_specialty Dose business.industry Bone age medicine.disease Growth hormone Adult height Idiopathic short stature law.invention Discontinuation Overig onderzoek afdeling Paediatrics Randomized controlled trial El Niño law Pediatrics Perinatology and Child Health medicine business |
| Zdroj: | Journal of Pediatrics, 132, pp. 455-460 Journal of Pediatrics, 132, 455-460 |
| ISSN: | 0022-3476 |
| Popis: | Objective: In children with idiopathic short stature (ISS) we studied the growth-promoting effect at 4 years of recombinant human growth hormone (rhGH) therapy in three dose regimens and evaluated whether increasing the dosage after the first year could prevent a decline in height velocity (HV). Design: Included were 223 patents who were treated with subcutaneous administrations of rhGH 6 days per week. They were randomized to three groups: 3 IU/m2 body surface/day, 4.5 IU/m2/day, and 3 IU/m2/day during the first year and 4.5 IU/m2/day thereafter, corresponding with dosages of 0.2 and 0.3 mg/kg body weight/week, respectively. Growth was compared with a standard of 229 untreated children with ISS [ISS standard]. Results: During the first year of treatment HV almost doubled and was higher with 4.5 IU/m2 than with 3 IU/m2. In the second year HV no longer differed among the groups, but increasing the dosage slowed the rate of the fall of HV. During 4 years of therapy the height SD score for age increased by a mean (SD) of 2.5 (1.0) [ISS standards], or 1.2 (0.7) (British standards), bone age increased by 4.8 (1.3) years, and predicted adult height SD score increased by 1.5 (0.7). After 4 years the results of the group with 4.5 IU/m2 were slightly better than those of the other groups. When dropouts were included in the analysis (assuming a stable height SD score after discontinuation of rhGH therapy), height gain was still significant. Conclusions: During 4 years of rhGH therapy, growth and final height prognosis improved, slightly more with 4.5 IU/m2 than with 3 IU/m2 or 3 to 4.5 IU/m2. However, bone age advanced on average 4.8 years during this period; therefore, any effect on final height will probably be modest. (J Pediatr 1998;132:455-60) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect